Recommendation

Unlock this content

In a recent newspaper interview marking his first anniversary at the helm of world-leading bionic ear implant manufacturer Cochlear, Chris Roberts reflected on the group’s turbulent year: ‘What continues to impress me is the fundamentals of the business, and by that I mean how well the technology works, its cost effectiveness, the size of the market, its potential and our competitive position.’

From one who felt the full wrath of the market just 12 months earlier, these sentiments provide more than a modicum of reassurance. Back then, with the world literally...

Latest Q&A With Our Experts

The most recent recommendation of the 'small-cap healthcare portfolio' stocks SOM and NAN is "Hold". but "neither company has the durability of a more established healthcare stock like Cochlear and Resmed". Yet Cochlear has a "Sell" recommendation...

InvestSMART Publishing Pty Ltd holds Australian Financial Securities Licence (AFSL) 282288.
The content of this website is general in nature and does not take the personal situation of any user of this website into consideration.
A user of this website should seek financial advice specific to that user’s situation before making any financial decision.
Past performance of any security or financial product is not a reliable indicator of future performance. InvestSMART Publishing Pty Ltd
encourages users of this website to view investing as a long-term pursuit.